Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Tuesday, 06'th Aug 2024
JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in moderate-to-severe plaque psoriasis expected to complete the primary endpoint portion of the studies in Q4 2024 JNJ-2113 Phase
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
09:15am, Wednesday, 31'st Jul 2024
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and c
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
07:00am, Monday, 22'nd Jul 2024
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Thursday, 18'th Jul 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through ou
3 Growth Stocks No One Is Watching (But They Should Be)
06:00am, Thursday, 11'th Jul 2024
Larger-capitalization enterprises command exceptional predictability with their businesses. They're often storied franchises with globally recognizable brands that people consume on the regular.
The 3 Best Biotech Stocks to Buy in June 2024
01:35pm, Wednesday, 05'th Jun 2024
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech's high-capital requirements and rising interest rate
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
07:30am, Friday, 31'st May 2024
NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open labe
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D.
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 07'th May 2024
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
01:01pm, Friday, 05'th Apr 2024
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
07:00am, Tuesday, 26'th Mar 2024
On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
10:56am, Monday, 18'th Mar 2024
The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
07:00am, Monday, 18'th Mar 2024
NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusferti
4 Stocks to Buy for Attractive Earnings Acceleration
07:16am, Friday, 15'th Mar 2024
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
